Evidence map›Paper›PMID 30992696›Full record

ArticleContrast media & molecular imaging2019

Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid.

Ulrika Jakobsson, Ermei Mäkilä, Anu J Airaksinen, Osku Alanen, Asenath Etilé, Ulli Köster, Sanjeev Ranjan, Jarno Salonen, Hélder A Santos, Kerttuli Helariutta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contrast media & molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ulrika JakobssonDepartment of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.
Ermei MäkiläDepartment of Physics and Astronomy, University of Turku, FI-20014 Turku, Finland.ORCID 0000-0002-8300-6533
Anu J AiraksinenDepartment of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.
Osku AlanenDepartment of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.
Asenath EtiléDepartment of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.
Ulli KösterInstitut Laue-Langevin, 71 Avenue des Martyrs, FI-38042 Grenoble Cedex 9, France.ORCID 0000-0001-5701-3249
Sanjeev RanjanDepartment of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.ORCID 0000-0001-6051-2663
Jarno SalonenDepartment of Physics and Astronomy, University of Turku, FI-20014 Turku, Finland.ORCID 0000-0002-5245-742X
Hélder A SantosDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland.ORCID 0000-0001-7850-6309
Kerttuli HelariuttaDepartment of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.ORCID 0000-0002-4143-912X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesoporous silicon (PSi) is biocompatible and tailorable material with high potential in drug delivery applications. Here, we report of an evaluation of PSi as a carrier platform for theranostics by delivering a radioactive ion beam- (RIB-) based radioactive lanthanoid into tumors in a mouse model of prostate carcinoma. Thermally hydrocarbonized porous silicon (THCPSi) wafers were implanted with

Indexed as

PorosityRadioisotopesSiliconRadioisotopesSilicon

Identifiers

PMID30992696
PMCPMC6434306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.